All Title Author
Keywords Abstract

PLOS ONE  2012 

Combination Treatment of Rosuvastatin or Atorvastatin, with Regular Exercise Improves Arterial Wall Stiffness in Patients with Coronary Artery Disease

DOI: 10.1371/journal.pone.0041369

Full-Text   Cite this paper   Add to My Lib


Objective Statin- and exercise-therapy are both clinically beneficial by preventing cardiovascular events in patients with coronary artery disease (CAD). However, there is no information on the vascular effects of the combination of statins and exercise on arterial wall stiffness in CAD patients. Methods The present study is a sub-analysis of PRESET study that determined the effects of 20-week treatment with statins (rosuvastatin, n = 14, atorvastatin, n = 14) combined with regular exercise on arterial wall stiffness assessed by measurement of brachial and ankle pulse wave velocity (baPWV) in CAD patients. Results The combination of statins and regular exercise significantly improved exercise capacity, lipid profile, including low- and high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (hs-CRP), baPWV (baseline: 1747±355, at 20 weeks of treatment: 1627±271 cm/s, p = 0.008), and basophil count (baseline: 42±32, 20 weeks: 26±15 cells/μL, p = 0.007), but had no effect on blood pressure (baseline: 125±22, 20 weeks: 121±16 mmHg). Changes in baPWV correlated significantly with changes in basophil count (r = 0.488, p = 0.008), but not with age, lipids profile, exercise capacity, or hs-CRP. Conclusion In CAD patients, the combination treatment with statins and exercise resulted in significant amelioration of arterial wall stiffness, at least in part, through reduction of circulating basophils.


[1]  Toyama K, Sugiyama S, Oka H, Sumida H, Ogawa H (2010) Exercise therapy correlates with improving renal function through modifying lipid metabolism in patients with cardiovascular disease and chronic kidney disease. J Cardiol 56: 142–146.
[2]  Goel K, Lennon RJ, Tilbury RT, Squires RW, Thomas RJ (2011) Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation 123: 2344–2352.
[3]  LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435.
[4]  Toyama K, Sugiyama S, Oka H, Iwasaki Y, Sumida H, et al. (2011) Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Atherosclerosis 217: 158–164.
[5]  Tomiyama H, Yamashina A (2010) Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J 74: 24–33.
[6]  Pietri P, Vyssoulis G, Vlachopoulos C, Zervoudaki A, Gialernios T, et al. (2006) Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 24: 2231–2238.
[7]  JAS (2007) [Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases]. J Atheroscler Thromb 5–57.
[8]  Imanishi R, Seto S, Toda G, Yoshida M, Ohtsuru A, et al. (2004) High brachial-ankle pulse wave velocity is an independent predictor of the presence of coronary artery disease in men. Hypertens Res 27: 71–78.
[9]  Vyssoulis G, Pietri P, Vlachopoulos C, Alexopoulos N, Kyvelou SM, et al. (2012) Early adverse effect of abnormal glucose metabolism on arterial stiffness in drug naive hypertensive patients. Diab Vasc Dis Res 9: 18–24.
[10]  Hongo M, Tsutsui H, Mawatari E, Hidaka H, Kumazaki S, et al. (2008) Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circ J 72: 722–728.
[11]  Wang F, Ye P, Luo L, Xiao W, Qi L, et al. (2011) Association of serum lipids with arterial stiffness in a population-based study in Beijing. Eur J Clin Invest 41: 929–936.
[12]  Wilkinson IB, Franklin SS, Cockcroft JR (2004) Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 44: 112–116.
[13]  Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, et al. (2004) Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 116: 682–692.
[14]  Michaelides AP, Soulis D, Antoniades C, Antonopoulos AS, Miliou A, et al. (2011) Exercise duration as a determinant of vascular function and antioxidant balance in patients with coronary artery disease. Heart 97: 832–837.
[15]  Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, et al. (2009) Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol 104: 464–469.
[16]  Rizos EC, Agouridis AP, Elisaf MS (2010) The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol 8: 638–644.
[17]  Karasuyama H, Mukai K, Obata K, Tsujimura Y, Wada T (2011) Nonredundant roles of basophils in immunity. Annu Rev Immunol 29: 45–69.
[18]  Dvorak AM (1997) New aspects of mast cell biology. Int Arch Allergy Immunol 114: 1–9.
[19]  Metzler B, Xu Q (1997) The role of mast cells in atherosclerosis. Int Arch Allergy Immunol 114: 10–14.
[20]  Davenport P, Tipping PG (2003) The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 163: 1117–1125.
[21]  Shimizu K, Shichiri M, Libby P, Lee RT, Mitchell RN (2004) Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 114: 300–308.
[22]  Tsuruda T, Kato J, Hatakeyama K, Kojima K, Yano M, et al. (2008) Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 102: 1368–1377.
[23]  Libby P, Shi GP (2007) Mast cells as mediators and modulators of atherogenesis. Circulation 115: 2471–2473.
[24]  Libby P, Ridker PM, Hansson GK (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54: 2129–2138.
[25]  Salonen R, Salonen JT (1990) Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis 81: 33–40.
[26]  Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340: 115–126.
[27]  Vieira RP, Claudino RC, Duarte AC, Santos AB, Perini A, et al. (2007) Aerobic exercise decreases chronic allergic lung inflammation and airway remodeling in mice. Am J Respir Crit Care Med 176: 871–877.
[28]  Cheng X, Ding Y, Xia C, Tang T, Yu X, et al. (2009) Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail 15: 158–162.
[29]  Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE (2008) Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118: 2506–2514.
[30]  Fearon IM, Faux SP (2009) Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol 47: 372–381.
[31]  Lee CW, Kang SJ, Ahn JM, Song HG, Lee JY, et al. (2012) Comparison of Effects of Atorvastatin (20 mg) Versus Rosuvastatin (10 mg) Therapy on Mild Coronary Atherosclerotic Plaques (from the ARTMAP Trial). Am J Cardiol 109: 1700–1704.
[32]  Rawlings R, Nohria A, Liu PY, Donnelly J, Creager MA, et al. (2009) Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol 103: 437–441.
[33]  Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, et al. (2002) Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 25: 359–364.
[34]  Amundsen EK, Henriksson CE, Holthe MR, Urdal P (2012) Is the blood basophil count sufficiently precise, accurate, and specific?: three automated hematology instruments and flow cytometry compared. Am J Clin Pathol 137: 86–92.


comments powered by Disqus